Market Size of Plasma Protease C1-inhibitor Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 6.90 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Plasma Protease C1-Inhibitor Market Analysis
The Plasma Protease C1-inhibitor Treatment Market is expected to experience a significant growth over the forecast period due to the growing incidence of hereditary angioedema (HAE). Hereditary angioedema is a potentially life-threatening genetic condition with incidence between 1 in 10,000 and 1 in 50,000 people according to HAE International (HAEi), the global umbrella organization for the world's HAE patient groups.
Additionally, increasing R&D investments, discovery of inhibitor drugs, increasing product approvals promising pipeline drugs and novel therapies for the treatment of hereditary angioedema are the few other factors driving the market globally.
Plasma Protease C1-Inhibitor Industry Segmentation
As per the scope of the report, plasma protease C1 inhibitor (C1 Inh) is a member of the serpin family of protease inhibitors and related proteins, and its mechanism of action is identical to those of the other protease inhibitor members of the family. SERPING1 forms a proteolytically inactive stoichiometric complex with the C1r or C1s proteases which will play a vital role in the regulation of blood coagulation, complement activation, generation of kinins and fibrinolysis. It is also an efficient FXIIa inhibitor. Mutations of the SERPING1 gene is associated with the adult macular degeneration which causes Hereditary Angioedema (HAE).
| By Drug Type | |
| C1-inhibitors | |
| Kallikrein Inhibitor | |
| Selective Bradykinin B2 Receptor Antagonist |
| By Dosage Form | |
| Lyphophlised | |
| Injectables |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Plasma Protease C1-inhibitor Market Size Summary
The Plasma Protease C1-inhibitor Treatment Market is poised for substantial expansion over the forecast period, driven by the increasing prevalence of hereditary angioedema (HAE), a serious genetic condition. The market's growth is further bolstered by heightened research and development investments, the discovery of new inhibitor drugs, and a promising pipeline of novel therapies and product approvals. The introduction of bradykinin B2 receptor antagonists, such as Icatibant, has been a significant advancement in treating acute HAE episodes, with regulatory approvals enhancing their availability. The market is also witnessing financial backing for clinical developments, as seen with Pharvaris's substantial funding to advance oral B2-receptor antagonists.
North America leads the global Plasma Protease C1-inhibitor market, attributed to the rising incidence of HAE and robust R&D investments. The region benefits from a well-established healthcare infrastructure, a growing number of product approvals, and the presence of major market players offering effective treatment options. The market is characterized by strategic activities such as partnerships, collaborations, and mergers among key players like CSL Behring LLC, Takeda Pharmaceutical Company Limited, and others. These dynamics, coupled with innovative treatment solutions, are expected to drive the market's growth, particularly in the United States, where significant regulatory approvals have been granted for routine prophylaxis therapies.
Plasma Protease C1-inhibitor Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Prevalence of Hereditary Angioedema (HAE)
-
1.2.2 Increasing Investments in the Research & Development Activities
-
-
1.3 Market Restraints
-
1.3.1 High Price of Esoteric Testing Procedures Restricting Market Entry
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Drug Type
-
2.1.1 C1-inhibitors
-
2.1.2 Kallikrein Inhibitor
-
2.1.3 Selective Bradykinin B2 Receptor Antagonist
-
-
2.2 By Dosage Form
-
2.2.1 Lyphophlised
-
2.2.2 Injectables
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Plasma Protease C1-inhibitor Market Size FAQs
What is the current Plasma Protease C1-inhibitor Market size?
The Plasma Protease C1-inhibitor Market is projected to register a CAGR of 6.90% during the forecast period (2024-2029)
Who are the key players in Plasma Protease C1-inhibitor Market?
CSL Behring LLC, Takeda Pharmaceutical Company Limited (Shire Pharmaceutical Holdings), Pharming Technologies B.V., KalVista Pharmaceuticals, Inc. and BioCryst Pharmaceuticals are the major companies operating in the Plasma Protease C1-inhibitor Market.
